Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients

Journal of the Peripheral Nervous System

Volumn 2, Issue 3, 1997, Pages 250-252

  Scarpini, Elio ^a   Sacilotto, Giorgio ^a   Baron, Pierluigi ^a   Cusini, Marco ^a   Scarlato, Guglielmo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetyl L carnitine; AIDS; Chronic pain; HIV+ neuropathy; Painful distal symmetrical polyneuropathy; Peripheral neuropathy; Therapy of peripheral neuropathies

Indexed keywords

ACETYLCARNITINE; NOOTROPIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY;

ACETYLCARNITINE; ADULT; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0031290516     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. McArthur JC, Johnson RT: Primary infection with human immunodeficiency virus. In: AIDS and Nervous System. (Rosenblum ML, Levy RM, Bredesen DE, eds). New York: Raven Press, 1988; 183-219.
2. Evans BK, Donley DK, Whitaker JN: Neurological manifestations of infection with the human immunodeficiency viruses. New York: Raven Press, 1991; 201-232.
3. Willner C, Low PA: Pharmacologic approaches to neuropathic pain. In: Peripheral Neuropathy (Dyck PJ, Thomas PK, eds). Philadelphia: WB Saunders Company, 1993; 1709-1720.
4. Onofrj M, Fulgente T, Melchionda D, Marchionni A, Tomasello F, Salpietro FM, Alafaci C, De Sanctis E, Pennisi G, Bella R, Ventura F, Morganti A: L-acetyl-carnitine as a new therapeutic approach for peripheral neuropathies with pain. Int. J. Pharm. Res. 1995; 15: 9-15.
5. Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D: Acetyl-L-Carnitine for symptomatic neuropathy. Diabetologia 1995; 38:123.
6. De Grandis D, Santoro L, Di Benedetto P: L-Acetylcarnitine in the treatment of patients with peripheral neuropathies. Clin. Drug Invest. 1995; 10:317-322.
7. Working Group of the American Academy of Neurology AIDS Task Force: Nomenclature and research case definitions for neurologic manifestations of Human Immunodeficiency Virus type 1 infection. Neurology 1991; 41:778-785.
8. Huskisson EC: Visual analogue scale. In: Pain Measurement and Assessment (Melzack R, ed). New York: Raven Press, 1983; 33.
9. Angelucci L, Ramacci MT, Taglialatela G, Hulsebosch C, Morgan B, Werrbach-Perez K, Perez-Polo R: Nerve growth factor binding activity in aged rat central nervous system: effect of acetyl-L-carnitine. J. Neurosci. Res. 1988; 20:491-496.
10. Rampello L, Giammona G, Aleppo G, Favit A, Fiore L: Trophic action of acetyl-L-carnitine in neuronal cultures. Acta Neurol. 1992; 14:15-21.
11. Gorio A, Di Giulio AM, Tenconi B, Donadoni L, Germani E, Bertelli A, Mantegazza P, Maccari F, Ramacci MT: Peptide alterations in autonomic diabetic neuropathy prevented by acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 1992;12:225-230.
12. Arienti G, Ramacci MT, Maccari F, Casu A, Corazzi L: Acetyl-L-carnitine influences the fluidity of brain microsomes and of liposomes made of rat brain microsomal lipid extracts. Neurochem. Res. 1992; 17:671-675.
13. Sass RL, Wermess P: Acetylcarnitine: on the relationship between structure and function. Biochem. Biophys. Res. Commun. 1973; 55:736-742.
14. Tesco G, Latorraca S, Persanti P, Piacentini S, Amaducci L, Sorbi S: Protection from oxygen radical damage in human diploid fibroblasts by acetyl-L-carnitine. Dementia 1992; 3:58-60.